India, June 9 -- Shares of Nuvalent, Inc. were surging around 39 percent in the pre-market activity on the Nasdaq, after the clinical-stage biopharma company focused on cancer therapies agreed to be acquired by British drug major GSK plc, in a deal valued at $10.6 billion or 8.0 billion pounds.
Further, GSK maintained its 2026 guidance range of 7 percent to 9 percent growth in core operating profit and core earnings per share.
The transaction, which would strengthen GSK's oncology pipeline with late-stage assets aimed at non-small cell lung cancer, will result in dilution to GSK's core earnings per share for the current year, fiscal 2027 and fiscal 2028, but accretion to core operating profit in 2027 and core earnings per share in 2029.
...